gpr40/ffar1

GPR40 FFAR1 modulator 1是一种针对Gq偶联的游离脂肪酸受体1 (GPR40 FFAR1) 的激动剂以及异构调节剂。

TUG-499 是一种选择性游离脂肪酸受体 1 (FFAR1 或 GPR40)激动剂（EC50 ： 7.39）。TUG-499对 FFAR1 或 GPR40的亲和力超过相关受体 FFA2、FFA3 和核受体 PPARγ，以及其他不同的受体、离子通道和转运蛋白。TUG-499 可用于研究 2 型糖尿病。

HWL-088 is a potent free fatty acid receptor 1 (FFA1 GPR40) agonist. HWL-088 significantly improves glucose tolerance in normal and diabetic models.

GW-1100是选择性的 GPR40 和 FFAR1 拮抗剂，可用于研究糖尿病和代谢疾病。

ZLY032 is a dual agonist of free fatty acid receptor 1 (FFAR1 GPR40; EC50= 68 nM in a FLIPR assay) and peroxisome proliferator-activated receptor δ (PPARδ; EC50= 102 nM in a reporter assay).1It is selective for FFAR1 and PPARδ over PPARα and PPARγ (EC50s = >10 μM for both). ZLY032 (40 mg kg, twice per day) reduces blood glucose levels in an oral glucose tolerance test and decreases plasma total cholesterol and triglyceride levels in theob obmouse model of metabolic disease.2It reduces hepatic steatosis and plasma alanine transaminase (ALT) and aspartate aminotransferase (AST) levels in a mouse model of non-alcoholic steatohepatitis (NASH) induced by a methionine and choline-deficient diet at the same dose. 1.Li, Z., Chen, Y., Zhou, Z., et al.Discovery of first-in-class thiazole-based dual FFA1 PPARδ agonists as potential anti-diabetic agentsEur. J. Med. Chem.164352-365(2019) 2.Li, Z., Zhou, Z., Hu, L., et al.ZLY032, the first-in-class dual FFA1 PPARδ agonist, improves glucolipid metabolism and alleviates hepatic fibrosisPharmacol Res.159105035(2020)

GPR40 agonist 6 (Compound 7a) 是游离脂肪酸受体 1的选择性激动剂（FFAR1或GPR40），其对于GPR40的EC50值为 0.058 μM。

DC260126 是一种 GPR40 (FFAR1)拮抗剂，对棕榈酸酯诱导的内质网应激和凋亡有保护作用。它剂量依赖性地抑制亚油酸、油酸、棕榈油酸和月桂酸刺激的 GPR40 介导的 Ca2+升高，IC50分别 6.28、5.96、7.07和4.58 μM。

BI-2081是一种GPR40 (FFAR1)部分激动剂，具有EC50值为4 nM。该化合物能诱导葡萄糖依赖性胰岛素释放，并降低血浆中葡萄糖含量，适用于研究代谢疾病，尤其是2型糖尿病。